statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares IDEAYA Announces Closing of Public Offering Including Full Exercise of...

IDEAYA Announces Pricing of Public Offering

IDEAYA Announces Pricing of Public Offering IDEAYA Announces Pricing of Public Offering PR Newswire SOUTH SAN FRANCISCO, Calif., July 9, 2024 SOUTH SAN FRANCISCO, Calif., July 9, 2024 /PRNewswire...

IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants PR Newswire SOUTH SAN FRANCISCO...

Top Stock Movers Now: Intel, Corning, SolarEdge, and More

Getty Images

 Key TakeawaysThe Nasdaq hit a record high in intraday trading Monday, July 8, 2024 as tech stocks gained.Intel shares surged after Melius Research suggested the stock could get a...

Buy Rating Affirmed for IDEAYA Biosciences Amid Promising Oncology Drug Trials and Market Potential

Analyst Tim Chiang of Capital One Financial reiterated a Buy rating on IDEAYA Biosciences (IDYA Research Report), retaining the price target of...

IDEAYA Biosciences Soars on Cancer Drug Study Results

Rolf Vennenbernd / picture alliance via Getty Images

 Key TakeawaysIDEAYA Biosciences reported positive results from a Phase 2 trial of its experimental drug to treat certain bladder and...

IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung Cancer

IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung Cancer IDEAYA Announces Positive...

IDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP-Deletion Urothelial and Lung Cancer on Monday, July 8, 2024

IDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP-Deletion Urothelial and Lung Cancer on Monday, July 8, 2024 IDEAYA Announces...

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire SOUTH SAN...

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy Combination in MTAP-Deletion Bladder Cancer

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy Combination in MTAP-Deletion Bladder Cancer IDEAYA Biosciences Announces First-Patient-In for...

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Volume	609,049.00
52-Wk High	$47.74
52-Wk Low	$21.22

IDYA Ideaya Biosciences Inc

About

Feed

News

Sentiment

Earnings

Fundamentals